Humanigen, Inc.: Clinical Trials

6 trials sponsored by Humanigen, Inc., newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 completed, 1 suspended, 1 terminated. 6 Phase 1, 3 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 16Completed 4, Suspended 1, Terminated 1
Phase 23Completed 2, Suspended 1

Follow Humanigen, Inc.: new trials by email

Trials (filtered) newest first · largest first

All 6 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study of Lenzilumab and Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma
Cyclophosphamide, Fludarabine, Lenzilumab - Relapsed/Refractory Large B-cell Lymphoma
Phase 1TerminatedKite, A Gilead Company62020-05-262024-03-04
A Trial of KB004 in Patients With Glioblastoma
KB004 - Glioblastoma
Phase 1CompletedOlivia Newton-John Cancer Research Institute122017-12-052021-11-04
Study of Lenzilumab in Previously Treated Patients With Chronic Myelomonocytic Leukemia (CMML)
lenzilumab - Chronic Myelomonocytic Leukemia (CMML)
Phase 1CompletedHumanigen, Inc.152016-07-012020-02-28
Study of KB004 in Subjects With Hematologic Malignancies (Myelodysplastic Syndrome, MDS, Myelofibrosis, MF)
KB004, Monoclonal Antibody - Myelodysplastic Syndrome (MDS), Myelofibrosis (MF)
Phase 1 / Phase 2SuspendedHumanigen, Inc.1202010-09-012015-11-17
Pilot Trial of KB001 in Mechanically-Ventilated Patients Colonized With Pseudomonas Aeruginosa
KB001, Placebo - Pseudomonas Aeruginosa, Ventilator Associated Pneumonia
Phase 1 / Phase 2CompletedHumanigen, Inc.362008-04-012009-07-31
Dose Escalation Study of KB001 in Cystic Fibrosis Patients Infected With Pseudomonas Aeruginosa
KB001, Placebo - Cystic Fibrosis
Phase 1 / Phase 2CompletedHumanigen, Inc.272008-03-012014-06-09

Conditions studied

Pseudomonas Infections (2)  ·  Cystic Fibrosis (1)  ·  Glioblastoma (1)  ·  Leukemia (1)  ·  Leukemia, Myelomonocytic, Chronic (1)  ·  Myelodysplastic Syndromes (1)  ·  Myeloproliferative Disorders (1)  ·  Neoplasms (1)  ·  Pneumonia, Ventilator-Associated (1)  ·  Primary Myelofibrosis (1)  ·  Recurrence (1)

Interventions

KB004 (2)  ·  lenzilumab (2)  ·  Antibodies, Monoclonal (1)  ·  Cyclophosphamide (1)  ·  axicabtagene ciloleucel (1)  ·  fludarabine (1)

Countries

United States (4)  ·  Australia (2)  ·  France (1)

Top investigators

Carlos Milla, MD (1)  ·  Hui Gan (1)  ·  Morgan Lam (1)  ·  Nestor A. Molfino, MD, MSc (1)  ·  Prof. Jean Chastre (1)

Results publications

PMID 24019259, PMID 27736729

NIH funding

2019 (1)